Últimas noticias sobre ADMA Biologics (NASDAQ:ADMA) Bolsa

ADMA Biologics

ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.

Long Ideas

News

Markets

Media

Trading Ideas

ADMA

DCTH

Jim Cramer analiza las perspectivas de ADMA, MP Materials y Delcath, destacando riesgos y oportunidades en un entorno de alta especulación.

Jim Cramer revela qué compañías son pura especulación y cuáles prometen

ADMA Biologics Inc

<h3>Gainers</h3>
<ul>
<li>TransCode Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) stock rose 20.0% to $0.65 during Thursday's regular session. The market value of their outstanding shares is at $11.2 million. </li>
<li>Vaccinex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCNX#NASDAQ">VCNX</a>) shares increased by 18.88% to $2.14. The company's market cap stands at $5.5 million. </li>
<li>NexGel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXGL#NASDAQ">NXGL</a>) stock increased by 17.65% to $2.82. The market value of their outstanding shares is at $17.8 million. </li>
<li>Cue Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUE#NASDAQ">CUE</a>) stock rose 17.01% to $1.41. The company's market cap stands at $84.8 million. </li>
<li>Genenta Science (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNTA#NASDAQ">GNTA</a>) shares increased by 15.81% to $6.5. The company's market cap stands at $118.4 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares moved upwards by 13.69% to $5.98. The company's market cap stands at $77.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Gritstone Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRTS#NASDAQ">GRTS</a>) stock declined by 64.2% to $0.07 during Thursday's regular session. The market value of their outstanding shares is at $8.3 million. </li>
<li>10x Genomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXG#NASDAQ">TXG</a>) stock fell 25.21% to $15.57. The company's market cap stands at $1.8 billion. </li>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) shares fell 21.17% to $0.4. The market value of their outstanding shares is at $2.2 million. </li>
<li>ADMA Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>) stock declined by 19.46% to $16.37. The market value of their outstanding shares is at $3.8 billion. </li>
<li>Tempest Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPST#NASDAQ">TPST</a>) shares decreased by 17.78% to $1.11. The company's market cap stands at $27.9 million. </li>
<li>Indivior (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDV#NASDAQ">INDV</a>) stock fell 17.27% to $7.81. The company's market cap stands at $1.0 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

GNTA

GRTS

HCTI

INDV

NXGL

RNAZ

Tempest Therapeutics, Inc. - Common Stock

TPST

VCNX

12 Health Care Stocks Moving In Thursday's Intraday Session

High-rolling investors have positioned themselves bearish on ADMA Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in ADMA often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 14 options trades for ADMA Biologics. This is not a typical pattern.
The sentiment among these major traders is split, with 21% bullish and 71% bearish. Among all the options we identified, there was one put, amounting to $40,000, and 13 calls, totaling $467,143.
<h3>What's The Price Target?</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $14.0 to $17.5 for ADMA Biologics during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for ADMA Biologics's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of ADMA Biologics's whale trades within a strike price range from $14.0 to $17.5 in the last 30 days. 
<h3>ADMA Biologics 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728577321_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADMA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$2.8</td>
<td>$2.4</td>
<td>$2.8</td>
<td>$17.50</td>
<td>$56.0K</td>
<td>3.5K</td>
<td>818</td>
</tr>
<tr>
<td>ADMA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$2.75</td>
<td>$2.15</td>
<td>$2.75</td>
<td>$17.50</td>
<td>$55.0K</td>
<td>3.5K</td>
<td>618</td>
</tr>
<tr>
<td>ADMA</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$5.5</td>
<td>$4.4</td>
<td>$4.95</td>
<td>$14.00</td>
<td>$49.5K</td>
<td>120</td>
<td>103</td>
</tr>
<tr>
<td>ADMA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$2.2</td>
<td>$2.0</td>
<td>$2.2</td>
<td>$17.50</td>
<td>$44.0K</td>
<td>3.5K</td>
<td>214</td>
</tr>
<tr>
<td>ADMA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$0.5</td>
<td>$0.2</td>
<td>$0.5</td>
<td>$15.00</td>
<td>$40.0K</td>
<td>1</td>
<td>2.6K</td>
</tr>
</tbody>
</table>

<h3>About ADMA Biologics</h3>
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.
Having examined the options trading patterns of ADMA Biologics, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>ADMA Biologics's Current Market Status</h3>
<ul>
<li>With a volume of 12,172,914, the price of ADMA is down -18.28% at $16.61. </li>
<li>RSI indicators hint that the underlying stock may be approaching oversold.</li>
<li>Next earnings are expected to be released in 27 days.</li>
</ul>
<h3>Professional Analyst Ratings for ADMA Biologics</h3>
A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $20.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Cantor Fitzgerald has revised its rating downward to Overweight, adjusting the price target to $20. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for ADMA Biologics with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

This Is What Whales Are Betting On ADMA Biologics

AstraZeneca (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/azn#NASDAQ">AZN</a>) announced that it has signed an exclusive license agreement with China-based CSPC Pharmaceutical Group Ltd for developing an early-stage, small molecule Lipoprotein (a) (Lp(a)) disruptor for helping patients with dyslipidaemia.
The latest agreement is likely to strengthen AstraZeneca&#39;s cardiovascular pipeline, which is being studied for treating various cardiovascular diseases.
Year to date, shares of AstraZeneca have rallied 14.1% compared with the industry&#39;s rise of 18.5%.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/fa/80674.jpg?v=23295027" />
Image Source: Zacks Investment Research
<h2>More on AZN&#39;s Latest Agreement</h2>
Per the deal, AZN will make an upfront payment of $100 million to CSPC. The company is also entitled to pay up to $1.92 billion for further development and commercialization milestones plus tiered royalties to CSPC.
Per the latest agreement with CSPC, AstraZeneca will gain access to the latter&#39;s pre-clinical candidate, YS2302018, an oral Lp(a) disruptor, and develop the same for various cardiovascular diseases. The company will develop YS2302018 alone or in combination studies, including with the oral small molecule PCSK9 inhibitor, AZD0780.
Discovered by CSPC, YS2302018 has been shown to effectively prevent the formation of Lp(a), a form of low-density lipoprotein&nbsp;that plays a key role in transporting cholesterol in the bloodstream.
Per the company, the addition of YS2302018 to AZN&#39;s cardiovascular pipeline might help patients to more effectively manage their dyslipidaemia and cardiometabolic diseases.
<h2>AZN&#39;s Airsupra Meet Goal in BATURA Study</h2>
In a separate press release, AstraZeneca announced positive data from the phase IIIb BATURA study, which evaluated its pressurized metered-dose inhaler (pMDI), Airsupra (albuterol/budesonide).
Data from the study showed that treatment with Airsupra led to a statistically significant and clinically meaningful reduction in the risk of a severe exacerbation when used as an as-needed rescue medication in response to symptoms versus as-needed albuterol in patients with intermittent or mild persistent asthma. This was the primary endpoint of the BATURA study.
Airsupra is approved for as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in people with asthma aged 18 years and above in the United States. It is the first and only anti-inflammatory rescue medication for the given condition.
<h2>AZN&#39;s Zacks Rank &amp; Other Stocks to Consider</h2>
AstraZeneca currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the biotech sector are ANI Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/anip#NASDAQ">ANIP</a>), ADMA Biologics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adma#NASDAQ">ADMA</a>) and Alnylam Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alny#NASDAQ">ALNY</a>), each sporting a Zacks Rank #1 (Strong Buy) at present. In the past 60 days, estimates for ANI Pharmaceuticals&#39; 2024 earnings per share have moved up from $4.53 to $4.81. Earnings per share estimates for 2025 have improved from $5.38 to $5.86. Year to date, shares of ANIP have increased 1.3%.
ANIP&#39;s earnings beat estimates in each of the trailing four quarters, with the average surprise being 31.32%.
In the past 60 days, estimates for ADMA Biologics&#39; 2024 earnings per share have increased from 35 cents to 49 cents. Earnings per share estimates for 2025 have improved from 53 cents to 64 cents. Year to date, shares of ADMA have surged 346.5%.
ADMA&#39;s earnings beat estimates in each of the trailing four quarters, with the average surprise being 105.63%.
In the past 60 days, estimates for Alnylam&#39;s 2024 loss per share have narrowed from $1.20 to 63 cents. Loss per share estimates for 2025 have narrowed from 34 cents to 27 cents. Year to date, shares of ALNY have rallied 39.4%.
ALNY&#39;s earnings beat estimates in each of the trailing four quarters, with the average surprise being 108.53%.
<a href="https://www.zacks.com/stock/news/2347767/astrazeneca-inks-agreement-to-boost-cardiovascular-pipeline?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2347767">To read this article on Zacks.com click here.</a>

Biotech

Earnings

Earnings Beats

Large Cap

Mid Cap

Small Cap

Events

Analyst Ratings

General

ALNY

ANIP

AstraZeneca Inks Agreement to Boost Cardiovascular Pipeline

In the latest quarter, 4 analysts provided ratings for ADMA Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>), showcasing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated ADMA Biologics and provided 12-month price targets. The average target is $18.25, accompanied by a high estimate of $20.00 and a low estimate of $15.00. Marking an increase of 32.73%, the current average surpasses the previous average price target of $13.75. 
<img src="https://www.benzinga.com/files/images/story/2024/1726866079_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
A comprehensive examination of how financial experts perceive ADMA Biologics is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$18.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$20.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$15.00</td>
<td>$10.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to ADMA Biologics. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of ADMA Biologics compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of ADMA Biologics's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into ADMA Biologics's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ADMA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on ADMA Biologics analyst ratings.</a>
<h2>Get to Know ADMA Biologics Better</h2>
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.
<h3>Understanding the Numbers: ADMA Biologics's Finances</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: ADMA Biologics's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 78.29%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: ADMA Biologics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 29.91%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): ADMA Biologics's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 18.75%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): ADMA Biologics's ROA excels beyond industry benchmarks, reaching 8.82%. This signifies efficient management of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.75, ADMA Biologics adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>What Are Analyst Ratings?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

In-Depth Examination Of 4 Analyst Recommendations For ADMA Biologics

Cantor Fitzgerald analyst Kristen Kluska reiterates ADMA Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>) with a Overweight and maintains $20 price target.

Price Target

Reiteration

Cantor Fitzgerald Reiterates Overweight on ADMA Biologics, Maintains $20 Price Target

Launched on 04/19/2011, the First Trust Small Cap Growth AlphaDEX ETF (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fyc#NASDAQ">FYC</a>) is a smart beta exchange traded fund offering broad exposure to the Style Box - Small Cap Growth category of the market.
<h2>What Are Smart Beta ETFs?</h2>
The ETF industry has long been dominated by products based on market cap weighted indexes, a strategy created to reflect the market or a particular market segment.
Market cap weighted indexes offer a low-cost, convenient, and transparent way of replicating market returns, and are a good option for investors who believe in market efficiency.
There are some investors, though, who think it&#39;s possible to beat the market with great stock selection; this group likely invests in another class of funds known as smart beta, which track non-cap weighted strategies.
Non-cap weighted indexes try to choose stocks that have a better chance of risk-return performance, which is based on specific fundamental characteristics, or a mix of other such characteristics.
Even though this space provides many choices to investors--think one of the simplest methodologies like equal-weighting and more complicated ones like fundamental and volatility/momentum based weighting--not all have been able to deliver first-rate results.
<h2>Fund Sponsor &amp; Index</h2>
The fund is sponsored by First Trust Advisors. It has amassed assets over $328.59 million, making it one of the average sized ETFs in the Style Box - Small Cap Growth. Before fees and expenses, this particular fund seeks to match the performance of the Nasdaq AlphaDEX Small Cap Growth Index.
The NASDAQ AlphaDEX Small Cap Growth Index is an enhanced which employs the AlphaDEX stock selection methodology to select stocks from the NASDAQ US 700 Small Cap Growth Index.
<h2>Cost &amp; Other Expenses</h2>
Cost is an important factor in selecting the right ETF, and cheaper funds can significantly outperform their more expensive cousins if all other fundamentals are the same.
Operating expenses on an annual basis are 0.70% for FYC, making it one of the most expensive products in the space.
It&#39;s 12-month trailing dividend yield comes in at 0.41%.
<h2>Sector Exposure and Top Holdings</h2>
Even though ETFs offer diversified exposure which minimizes single stock risk, it is still important to look into a fund&#39;s holdings before investing. Luckily, most ETFs are very transparent products that disclose their holdings on a daily basis.
For FYC, it has heaviest allocation in the Healthcare sector --about 22.90% of the portfolio --while Industrials and Information Technology round out the top three.
When you look at individual holdings, Adma Biologics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adma#NASDAQ">ADMA</a>) accounts for about 0.92% of the fund&#39;s total assets, followed by Mirum Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mirm#NASDAQ">MIRM</a>) and Zeta Global Holdings Corp. (class A) (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/zeta#NYSE">ZETA</a>).
Its top 10 holdings account for approximately 7.9% of FYC&#39;s total assets under management.
<h2>Performance and Risk</h2>
So far this year, FYC has added roughly 16.21%, and was up about 25.24% in the last one year (as of 09/17/2024). During this past 52-week period, the fund has traded between $51.50 and $73.05.
The fund has a beta of 1.18 and standard deviation of 24.03% for the trailing three-year period, which makes FYC a high risk choice in this particular space. With about 265 holdings, it effectively diversifies company-specific risk.
<h2>Alternatives</h2>
First Trust Small Cap Growth AlphaDEX ETF is a reasonable option for investors seeking to outperform the Style Box - Small Cap Growth segment of the market. However, there are other ETFs in the space which investors could consider.
IShares Russell 2000 Growth ETF (ARCA:IWO) tracks Russell 2000 Growth Index and the Vanguard Small-Cap Growth ETF (ARCA:VBK) tracks CRSP U.S. Small Cap Growth Index. IShares Russell 2000 Growth ETF has $11.60 billion in assets, Vanguard Small-Cap Growth ETF has $17.61 billion. IWO has an expense ratio of 0.24% and VBK charges 0.07%.
Investors looking for cheaper and lower-risk options should consider traditional market cap weighted ETFs that aim to match the returns of the Style Box - Small Cap Growth.
<a href="https://www.zacks.com/stock/news/2336915/is-first-trust-small-cap-growth-alphadex-etf-fyc-a-strong-etf-right-now?cid=CS-BENZ-FT-smart_beta_etf-2336915">To read this article on Zacks.com click here.</a>

Sector ETFs

Dividends

Health Care

ETFs

MIRM

ZETA

Is First Trust Small Cap Growth AlphaDEX ETF a Strong ETF Right Now?

ADMA Biologics Will Join The S&P Smallcap 600 Index, Effective Prior To The Open Of Trading On Monday, September 23

Launched on 04/19/2011, the First Trust Small Cap Growth AlphaDEX ETF (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fyc#NASDAQ">FYC</a>) is a passively managed exchange traded fund designed to provide a broad exposure to the Small Cap Growth segment of the US equity market.
The fund is sponsored by First Trust Advisors. It has amassed assets over $314.36 million, making it one of the average sized ETFs attempting to match the Small Cap Growth segment of the US equity market.
<h2>Why Small Cap Growth</h2>
With more potential comes more risk, and small cap companies, with market capitalization below $2 billion, epitomizes this way of thinking.
Qualities of growth stocks include faster growth rates compared to the broader market, as well as higher valuations and higher than average sales and earnings growth rates. Additionally, growth stocks have a greater level of risk associated with them. They are likely to outperform value stocks in strong bull markets but over the longer-term, value stocks have delivered better returns than growth stocks in almost all markets.
<h2>Costs</h2>
Expense ratios are an important factor in the return of an ETF and in the long term, cheaper funds can significantly outperform their more expensive counterparts, other things remaining the same.
Annual operating expenses for this ETF are 0.70%, making it one of the most expensive products in the space.
It has a 12-month trailing dividend yield of 0.43%.
<h2>Sector Exposure and Top Holdings</h2>
ETFs offer a diversified exposure and thus minimize single stock risk but it is still important to delve into a fund&#39;s holdings before investing. Most ETFs are very transparent products and many disclose their holdings on a daily basis.
This ETF has heaviest allocation to the Healthcare sector--about 22.30% of the portfolio. Industrials and Information Technology round out the top three.
Looking at individual holdings, Adma Biologics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adma#NASDAQ">ADMA</a>) accounts for about 0.92% of total assets, followed by Mirum Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mirm#NASDAQ">MIRM</a>) and Zeta Global Holdings Corp. (class A) (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/zeta#NYSE">ZETA</a>).
The top 10 holdings account for about 7.9% of total assets under management.
<h2>Performance and Risk</h2>
FYC seeks to match the performance of the Nasdaq AlphaDEX Small Cap Growth Index before fees and expenses. The NASDAQ AlphaDEX Small Cap Growth Index is an enhanced which employs the AlphaDEX stock selection methodology to select stocks from the NASDAQ US 700 Small Cap Growth Index.
The ETF has added roughly 11.05% so far this year and it&#39;s up approximately 18.52% in the last one year (as of 09/12/2024). In the past 52-week period, it has traded between $51.50 and $72.61.
The ETF has a beta of 1.18 and standard deviation of 23.97% for the trailing three-year period, making it a high risk choice in the space. With about 265 holdings, it effectively diversifies company-specific risk.
<h2>Alternatives</h2>
First Trust Small Cap Growth AlphaDEX ETF carries a Zacks ETF Rank of 3 (Hold), which is based on expected asset class return, expense ratio, and momentum, among other factors. Thus, FYC is a good option for those seeking exposure to the Style Box - Small Cap Growth area of the market. Investors might also want to consider some other ETF options in the space.
The iShares Russell 2000 Growth ETF (ARCA:IWO) and the Vanguard Small-Cap Growth ETF (ARCA:VBK) track a similar index. While iShares Russell 2000 Growth ETF has $11.17 billion in assets, Vanguard Small-Cap Growth ETF has $17.01 billion. IWO has an expense ratio of 0.24% and VBK charges 0.07%.
<h2>Bottom-Line</h2>
While an excellent vehicle for long term investors, passively managed ETFs are a popular choice among institutional and retail investors due to their low costs, transparency, flexibility, and tax efficiency.
<a href="https://www.zacks.com/stock/news/2335016/should-first-trust-small-cap-growth-alphadex-etf-fyc-be-on-your-investing-radar?cid=CS-BENZ-FT-style_box_etf-2335016">To read this article on Zacks.com click here.</a>

Should First Trust Small Cap Growth AlphaDEX ETF Be on Your Investing Radar?

ADMA Biologics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>) shares are moving higher after it was announced that the company will join the <a href="https://www.benzinga.com//node/40651658">S&amp;P SmallCap 600</a>.
The Details: ADMA Biologics will replace Olympic Steel Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZEUS#NASDAQ">ZEUS</a>) in the S&amp;P SmallCap 600.
This change will take effect before the market opens on September 23. Other companies in the healthcare sector are also joining the index, including TG Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGTX#NASDAQ">TGTX</a>). 
How To Buy ADMA Biologics Shares
By now you're likely curious about how to participate in the market for ADMA Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>) &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so.
In the the case of ADMA Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>), which is trading at $18.84 as of publishing time, $100 would buy you 5.31 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
Related Link: <a href="https://www.benzinga.com/markets/equities/24/09/40777323/nasdaq-surges-over-1-us-wholesale-inventories-rise-0-2-in-july">Nasdaq Surges Over 1%; US Wholesale Inventories Rise 0.2% In July</a>
AMDA Price Action: At the time of writing, ADMA Biologics stock is moving 13.3% higher at $18.43, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: Unsplash/ Volodymyr Hryshchenko

TGTX

ZEUS

What's Going On With ADMA Biologics Stock Monday?

U.S. stocks were higher, with the Dow Jones index gaining around 400 points on Monday.
Shares of Terns Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TERN#NASDAQ">TERN</a>) rose sharply in today's <a href="https://www.benzinga.com/quote/TERN/news">pre-market trading session.</a>
The company announced a top-line data from its Phase 1 randomized, double-blind, placebo-controlled single and multiple-ascending dose trial to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of TERN-601 dosed once-daily in healthy adults with obesity or overweight.
Terns Pharmaceuticals shares jumped 20.2% to $9.38 on Monday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Summit Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) shares jumped 45.2% to $17.82 after the announced its lung cancer candidate has surpassed Merck&#8217;s multi-billion dollar Keytruda, cutting the risk of disease or death by half.</li>
<li>Relay Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLAY#NASDAQ">RLAY</a>) gained 41% to $8.80 after the company reported interim data for its breast cancer treatment.</li>
<li>ADMA Biologics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>) climbed 16.5% to $18.95 after it was announced the company will join the S&amp;P SmallCap 600.</li>
<li>Emerald Holding, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EEX#NYSE">EEX</a>) gained 15% to $6.16.</li>
<li>Stardust Power Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDST#NASDAQ">SDST</a>) climbed 14% to $7.90.</li>
<li>SunOpta Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STKL#NASDAQ">STKL</a>) gained 13.4% to $6.36.</li>
<li>Mercer International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MERC#NASDAQ">MERC</a>) rose 12.8% to $6.41. Adient will replace Mercer International in the S&amp;P SmallCap 600.</li>
<li>Zurn Elkay Water Solutions Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZWS#NYSE">ZWS</a>) gained 12.6% to $33.46.</li>
<li>Applied Digital Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NASDAQ">APLD</a>) jumped 11.8% to $5.09. Needham analyst John Todaro reiterated Applied Digital with a Buy and maintained a price target of $11.</li>
<li>Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) climbed 10.5% to $33.51 after the company announced an enterprise agreement with BP to extend their strategic relationship and introduce new artificial intelligence capabilities with Palantir&#8217;s AIP software.</li>
<li>Inspire Medical Systems, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INSP#NYSE">INSP</a>) gained 10.3% to $217.08 after it was announced the company will join the SmallCap 600.</li>
<li>Impinj, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PI#NASDAQ">PI</a>) gained 10.2% to $172.65 after it was announced the company will join the S&amp;P SmallCap 600.</li>
<li>Compass, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COMP#NYSE">COMP</a>) rose 10.2% to $5.68.</li>
<li>Trump Media &amp; Technology Group Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) gained 10% to $18.82.</li>
<li>ImmunityBio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>) rose 9% to $3.6850 after the company presented long-term overall survival data in non-small cell lung cancer patients and announced registrational intent Phase 3 trials with ANKTIVA and checkpoint immunotherapy at the World Conference on Lung Cancer.</li>
<li>Hamilton Lane Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLNE#NASDAQ">HLNE</a>) gained 7.9% to $157.26 after ht was announced the company will be added to the S&amp;P MidCap 400.</li>
<li>MicroStrategy Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) gained 6.6% to $121.81.</li>
<li>The Boeing Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) gained 3.7% to $163.55 following the announcement of a preliminary agreement between the company and its workers' union, potentially averting a strike that could have disrupted operations.</li>
<li>Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) rose 3.6% to $218.32 after its supplier Panasonic announced it completed preparations for mass production of high-capacity EV batteries. It&#8217;s set to produce 4680 cells at the Wakayama plant.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://editorial.benzinga.com/wp-admin/post.php?post=537615&amp;action=edit">McKesson, News Corporation And 2 Other Stocks Executives Are Selling</a></li>
</ul>

Intraday Update

APLD

COMP

HLNE

IBRX

INSP

MERC

MSTR

PLTR

RLAY

SDST

SMMT

STKL

TERN

TSLA

Terns Pharmaceuticals, Boeing, Tesla And Other Big Stocks Moving Higher On Monday

WIIM

ADMA Biologics shares are trading higher after it was announced the company will join the S&P SmallCap 600.

On CNBC's &#8220;Mad Money Lightning Round,&#8221; Jim Cramer said, &#8220;This is a very speculative situation,&#8221; when asked about ADMA Biologics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>). &#8220;Any time there's immunity-compromised patients, there's some <a href="https://www.benzinga.com/quote/ADMA">big money down the road,&#8221; he added.</a>
On Aug. 8, ADMA Biologics reported better-than-expected second-quarter financial results and raised its FY24 and FY25 revenue guidance above estimates. 
The company reported quarterly earnings of 13 cents per share which beat the analyst consensus estimate of 7 cents per share. The company reported quarterly sales of about $107.2 million which beat the analyst consensus estimate of $86.4 million.
&#8220;This is one of those situations that is very difficult,&#8221; Cramer on MP Materials Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MP#NYSE">MP</a>). &#8220;If they don't pull out of the tailspin of losses, then it just doesn't matter.&#8221;
On July 25, Marine Prods posted better-than-expected sales for its second quarter. Marine Prods reported quarterly earnings of 14 cents per share which met the analyst consensus estimate. The company reported quarterly sales of $69.55 million which beat the analyst consensus estimate of $65.35 million.
When asked about Delcath Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCTH#NASDAQ">DCTH</a>), he said, &#8220;There's no investing. At this point, it is speculating.&#8221;
On Aug. 28, Delcath Systems announced positive results from independent study on liver-directed therapy for uveal melanoma patients.
Price Action:
<ul>
<li>ADMA Biologics shares fell 0.1% to settle at $17.22 on Thursday.</li>
<li>MP Materials shares gained 3.2% to close at $12.90.</li>
<li>Delcath Systems shares gained 1.2% to close at $10.77.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/08/40624754/top-2-materials-stocks-that-are-ticking-portfolio-bombs">Top 2 Materials Stocks That Are Ticking Portfolio Bombs</a></li>
</ul>
Image: Shutterstock

'This Is A Very Speculative Situation,' Jim Cramer On ADMA Biologics

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>VERV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$5.00</td>
<td>$121.2K</td>
<td>22</td>
<td>1.0K</td>
</tr>
<tr>
<td>GSK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$41.00</td>
<td>$28.0K</td>
<td>1.8K</td>
<td>913</td>
</tr>
<tr>
<td>CLOV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$2.00</td>
<td>$46.2K</td>
<td>7.3K</td>
<td>550</td>
</tr>
<tr>
<td>CRBP</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$50.00</td>
<td>$39.1K</td>
<td>1.5K</td>
<td>183</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$900.00</td>
<td>$56.1K</td>
<td>784</td>
<td>142</td>
</tr>
<tr>
<td>ADMA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$17.50</td>
<td>$28.0K</td>
<td>3.4K</td>
<td>117</td>
</tr>
<tr>
<td>TNDM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$45.00</td>
<td>$26.4K</td>
<td>10</td>
<td>100</td>
</tr>
<tr>
<td>AZN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$80.00</td>
<td>$32.0K</td>
<td>1.0K</td>
<td>52</td>
</tr>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$72.50</td>
<td>$61.5K</td>
<td>8</td>
<td>46</td>
</tr>
<tr>
<td>ELV</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$550.00</td>
<td>$26.4K</td>
<td>184</td>
<td>26</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• Regarding VERV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERV#NASDAQ">VERV</a>), we observe a put option sweep with bullish sentiment. It expires in 186 day(s) on February 21, 2025. Parties traded 1000 contract(s) at a $5.00 strike. This particular put needed to be split into 15 different trades to become filled. The total cost received by the writing party (or parties) was $121.2K, with a price of $120.0 per contract. There were 22 open contracts at this strike prior to today, and today 1005 contract(s) were bought and sold. 
• Regarding GSK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>), we observe a call option sweep with bearish sentiment. It expires in 32 day(s) on September 20, 2024. Parties traded 200 contract(s) at a $41.00 strike. This particular call needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $28.0K, with a price of $140.0 per contract. There were 1865 open contracts at this strike prior to today, and today 913 contract(s) were bought and sold. 
• For CLOV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLOV#NASDAQ">CLOV</a>), we notice a call option sweep that happens to be bearish, expiring in 151 day(s) on January 17, 2025. This event was a transfer of 350 contract(s) at a $2.00 strike. This particular call needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $46.2K, with a price of $132.0 per contract. There were 7304 open contracts at this strike prior to today, and today 550 contract(s) were bought and sold. 
• For CRBP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBP#NASDAQ">CRBP</a>), we notice a put option sweep that happens to be bullish, expiring in 60 day(s) on October 18, 2024. This event was a transfer of 38 contract(s) at a $50.00 strike. This particular put needed to be split into 9 different trades to become filled. The total cost received by the writing party (or parties) was $39.1K, with a price of $1030.0 per contract. There were 1500 open contracts at this strike prior to today, and today 183 contract(s) were bought and sold. 
• For LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we notice a call option trade that happens to be bearish, expiring in 60 day(s) on October 18, 2024. This event was a transfer of 10 contract(s) at a $900.00 strike. The total cost received by the writing party (or parties) was $56.1K, with a price of $5617.0 per contract. There were 784 open contracts at this strike prior to today, and today 142 contract(s) were bought and sold. 
• For ADMA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>), we notice a call option trade that happens to be bullish, expiring in 151 day(s) on January 17, 2025. This event was a transfer of 100 contract(s) at a $17.50 strike. The total cost received by the writing party (or parties) was $28.0K, with a price of $280.0 per contract. There were 3492 open contracts at this strike prior to today, and today 117 contract(s) were bought and sold. 
• For TNDM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>), we notice a put option sweep that happens to be bearish, expiring in 32 day(s) on September 20, 2024. This event was a transfer of 98 contract(s) at a $45.00 strike. This particular put needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $26.4K, with a price of $270.0 per contract. There were 10 open contracts at this strike prior to today, and today 100 contract(s) were bought and sold. 
• For AZN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>), we notice a call option trade that happens to be bearish, expiring in 60 day(s) on October 18, 2024. This event was a transfer of 50 contract(s) at a $80.00 strike. The total cost received by the writing party (or parties) was $32.0K, with a price of $640.0 per contract. There were 1099 open contracts at this strike prior to today, and today 52 contract(s) were bought and sold. 
• For CVS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), we notice a put option sweep that happens to be bullish, expiring in 214 day(s) on March 21, 2025. This event was a transfer of 42 contract(s) at a $72.50 strike. This particular put needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $61.5K, with a price of $1465.0 per contract. There were 8 open contracts at this strike prior to today, and today 46 contract(s) were bought and sold. 
• For ELV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>), we notice a put option trade that happens to be bearish, expiring in 32 day(s) on September 20, 2024. This event was a transfer of 20 contract(s) at a $550.00 strike. The total cost received by the writing party (or parties) was $26.4K, with a price of $1320.0 per contract. There were 184 open contracts at this strike prior to today, and today 26 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CLOV

CRBP

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

TNDM

VERV

10 Health Care Stocks Whale Activity In Today's Session

Financing

ADMA Biologics Repaid $30M From Original $72.5M Revolving Credit Facility With Ares Capital

While &quot;the trend is your friend&quot; when it comes to short-term investing or trading, timing entries into the trend is a key determinant of success. And increasing the odds of success by making sure the sustainability of a trend isn&#39;t easy.
Often, the direction of a stock&#39;s price movement reverses quickly after taking a position in it, making investors incur a short-term capital loss. So, it&#39;s important to ensure that there are enough factors -- such as sound fundamentals, positive earnings estimate revisions, etc. -- that could keep the momentum in the stock going.
Our &quot;Recent Price Strength&quot; screen, which is created on a unique short-term trading strategy, could be pretty useful in this regard. This predefined screen makes it really easy to shortlist the stocks that have enough fundamental strength to maintain their recent uptrend. Also, the screen passes only the stocks that are trading in the upper portion of their 52-week high-low range, which is usually an indicator of bullishness.
There are several stocks that passed through the screen:
<h2>Adma Biologics</h2>
Adma Biologics (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adma#NASDAQ">ADMA</a>) is one of them. Here are the key reasons why this stock is a solid choice for &quot;trend&quot; investing.
A solid price increase over a period of 12 weeks reflects investors&#39; continued willingness to pay more for the potential upside in a stock. ADMA is quite a good fit in this regard, gaining 73.3% over this period.
However, it&#39;s not enough to look at the price change for around three months, as it doesn&#39;t reflect any trend reversal that might have happened in a shorter time frame. It&#39;s important for a potential winner to maintain the price trend. A price increase of 24.9% over the past four weeks ensures that the trend is still in place for the stock of this infectious disease drug developer.
Moreover, ADMA is currently trading at 95% of its 52-week High-Low Range, hinting that it can be on the verge of a breakout.
Looking at the fundamentals, the stock currently carries a Zacks Rank #1 (Strong Buy), which means it is in the top 5% of more than the 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS surprises -- the key factors that impact a stock&#39;s near-term price movements.
The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988.
Another factor that confirms the company&#39;s fundamental strength is its Average Broker Recommendation of #1 (Strong Buy). This indicates that the brokerage community is highly optimistic about the stock&#39;s near-term price performance.
So, the price trend in ADMA may not reverse anytime soon.
<a href="https://www.zacks.com/stock/news/2320491/adma-biologics-adma-is-on-the-move-here-s-why-the-trend-could-be-sustainable?cid=CS-BENZ-FT-tale_of_the_tape|recent_price_strength_screen-2320491">To read this article on Zacks.com click here.</a>

Adma Biologics is on the Move, Here's Why the Trend Could be Sustainable

Ratings for ADMA Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for ADMA Biologics, presenting an average target of $16.75, a high estimate of $20.00, and a low estimate of $14.00. Witnessing a positive shift, the current average has risen by 42.55% from the previous average price target of $11.75.
<img src="https://www.benzinga.com/files/images/story/2024/1723464079_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A comprehensive examination of how financial experts perceive ADMA Biologics is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$18.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$20.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$15.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Anthony Petrone</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Buy</td>
<td>$14.00</td>
<td>$12.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to ADMA Biologics. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of ADMA Biologics compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for ADMA Biologics's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of ADMA Biologics's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ADMA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on ADMA Biologics analyst ratings.</a>
<h2>Get to Know ADMA Biologics Better</h2>
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.
<h3>Financial Milestones: ADMA Biologics's Journey</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Over the 3 months period, ADMA Biologics showcased positive performance, achieving a revenue growth rate of 78.29% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: ADMA Biologics's net margin is impressive, surpassing industry averages. With a net margin of 29.91%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): ADMA Biologics's ROE stands out, surpassing industry averages. With an impressive ROE of 18.75%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): ADMA Biologics's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 8.82%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.75, ADMA Biologics adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: Simplified</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Assessing ADMA Biologics: Insights From 4 Financial Analysts

HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintains ADMA Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>) with a Buy and raises the price target from $10 to $18.

HC Wainwright & Co. Maintains Buy on ADMA Biologics, Raises Price Target to $18

These seven mid-cap stocks were the best performers in the last week. Are they in your portfolio?
<ol>
<li>Lumen Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUMN#NYSE">LUMN</a>) shares jumped 113.82% after the company <a href="https://www.benzinga.com//node/40204727" target="_blank" rel="noreferrer noopener">reported second-quarter revenue results</a>. Multiple analysts either upgraded or <a href="https://www.benzinga.com//node/40221474" target="_blank" rel="noreferrer noopener">raised price targets on the stock</a>.</li>
<li>Upstart Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>) stock jumped 73.65% after the company <a href="https://www.benzinga.com//node/40227720" target="_blank" rel="noreferrer noopener">reported strong second-quarter results</a>. Many analysts <a href="https://www.benzinga.com//node/40229270" target="_blank" rel="noreferrer noopener">upped the price target on the stock</a>.</li>
<li>ADMA Biologics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>) stock gained 52.58% in the last week on reporting better-than-expected Q2 financial results.</li>
<li>Sweetgreen Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SG#NYSE">SG</a>) stock gained 47.35% after the company reported <a href="https://www.benzinga.com//node/40284819" target="_blank" rel="noreferrer noopener">better-than-expected second-quarter financial results</a> and issued a strong FY24 revenue outlook. Several analysts<a href="https://www.benzinga.com/quote/SG/analyst-ratings" target="_blank" rel="noreferrer noopener"> raised the company&#8217;s price target</a>.</li>
<li>Veracyte, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>) shares escalated 46.57% after the company reported <a href="https://www.benzinga.com//node/40229725" target="_blank" rel="noreferrer noopener">better-than-expected second-quarter financial results</a>.</li>
<li>Clear Secure, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YOU#NYSE">YOU</a>) stock increased 38.83% after the company reported second-quarter financial results and issued Q3 <a href="https://www.benzinga.com//node/40181525" target="_blank" rel="noreferrer noopener">revenue guidance above estimates</a>.</li>
<li>Core Scientific, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORZ#NASDAQ">CORZ</a>) shares upped 38.37% after the company announced that CoreWeave exercised an additional <a href="https://www.benzinga.com//node/40194866" target="_blank" rel="noreferrer noopener">contract option</a>.</li>
</ol>
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/08/40303623/warner-bros-airbnb-and-monster-beverage-are-among-top-10-large-cap-losers-last-week-aug-4-aug-10-a" target="_blank" rel="noreferrer noopener">Warner Bros, Airbnb And Monster Beverage Are Among Top 10 Large Cap Losers  Last Week (Aug 4-Aug 10): Are The Others In Your Portfolio?</a></li>
<li><a href="https://www.benzinga.com/news/24/08/40303526/shopify-palantir-and-uber-are-among-top-10-large-cap-gainers-last-week-aug-4-aug-10-are-the-others-i" target="_blank" rel="noreferrer noopener">Shopify, Palantir And Uber Are Among Top 10 Large Cap Gainers Last Week (Aug 4-Aug 10): Are The Others In Your Portfolio?</a></li>
</ul>
Photo courtesy of Lumen

Core Scientific, Inc. - Class A Common Stock

CORZ

LUMN

UPST

VCYT

Lumen Tech & Upstart Are Among Top 7 Mid Cap Gainers Last Week (Aug 4-Aug 10): Are The Others In Your Portfolio?

U.S. stocks were mixed, with the Dow Jones index gaining around 0.1% on Friday.
Shares of Expedia Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>) rose sharply during Friday's session after the company reported<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40288024/expedias-q2-triumph-analysts-highlight-vrbo-as-bright-spot-praise-growth-in-busines"> better-than-expected second-quarter financial results.</a>
Expedia Group reported quarterly earnings of $3.51 per share which beat the analyst consensus estimate of $3.06 per share. The company reported quarterly sales of $3.558 billion which beat the analyst consensus estimate of $3.534 billion.
Expedia Group shares jumped 9.4% to $129.02 on Friday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Blend Labs, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLND#NYSE">BLND</a>) gained 32% to $3.55 after the company reported better-than-expected second-quarter financial results. Also, William Blair upgraded the stock from Market Perform to Outperform.</li>
<li>Doximity, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>) gained 31.6% to $33.82 after the company reported better-than-expected first-quarter financial results. Additionally, the company issued FY24 revenue guidance above estimates.</li>
<li>ADMA Biologics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>) shares surged 29.5% to $15.80 after the company reported better-than-expected second-quarter financial results and raised its FY24 and FY25 revenue guidance above estimates.</li>
<li>Sweetgreen, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SG#NYSE">SG</a>) climbed 26.2% to $33.13 after the company reported better-than-expected second-quarter revenue results.</li>
<li>Evolent Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) rose 24.2% to $25.92 after the company reported better-than-expected quarterly financial results. Also, Truist Securities upgraded the stock from Hold to Buy and raised its price target from $28 to $33.</li>
<li>Iovance Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOVA#NASDAQ">IOVA</a>) gained 20.2% to $9.54 after the company reported better-than-expected second-quarter financial results and issued third-quarter product revenue guidance above estimates.</li>
<li>CarGurus, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARG#NASDAQ">CARG</a>) gained 18.2% to $26.48 after the company reported better-than-expected second-quarter financial results and issued third-quarter non-GAAP EPS guidance above estimates.</li>
<li>IAMGOLD Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IAG#NYSE">IAG</a>) gained 15.6% to $4.2550 after the company reported better-than-expected second-quarter financial results.</li>
<li>Genpact Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/G#NYSE">G</a>) rose 14.9% to $37.23 after the company reported better-than-expected second-quarter financial results and issued FY24 revenue guidance above estimates. Also, the company raised its FY24 EPS guidance above estimates.</li>
<li>Paymentus Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAY#NYSE">PAY</a>) climbed 13.7% to $22.19 after the company reported better-than-expected second-quarter financial results and issued FY24 revenue guidance above estimates.</li>
<li>DigitalOcean Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCN#NYSE">DOCN</a>) rose 13.4% to $32.99 after the company reported better-than-expected second-quarter financial results and issued FY24 revenue guidance above estimates.</li>
<li>Rocket Lab USA, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) gained 12.2% to $5.35 after the company reported better-than-expected second-quarter financial results. Also, the company announced it hot fired its new rocket engine Archimedes for the first time.</li>
<li>Akamai Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKAM#NASDAQ">AKAM</a>) rose 11.3% to $101.91 after the company reported better-than-expected second-quarter financial results.</li>
<li>Avidity Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNA#NASDAQ">RNA</a>) gained 10.6% to $46.31.</li>
<li>The Trade Desk, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) rose 9.6% to $96.81 after the company reported better-than-expected second-quarter financial results and issued third-quarter revenue guidance above estimates. Also, Keybanc and Susquehanna raised their respective price targets on the stock.</li>
<li>DXC Technology Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DXC#NYSE">DXC</a>) climbed 7.2% to $19.64 after the company reported better-than-expected quarterly financial results..</li>
<li>Eli Lilly and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) gained 5.8% to $894.83.</li>
</ul>
Now Read This:<a href="https://www.benzinga.com/news/24/08/40278354/top-2-risk-off-stocks-that-may-implode-in-august"> </a>
<ul>
<li><a href="https://www.benzinga.com/news/24/08/40278354/top-2-risk-off-stocks-that-may-implode-in-august">Top 2 Risk Off Stocks That May Implode In August</a></li>
</ul>

AKAM

BLND

CARG

DOCN

DOCS

EXPE

IOVA

RKLB

Expedia Posts Upbeat Earnings, Joins Akamai Technologies, Trade Desk, DXC Technology And Other Big Stocks Moving Higher On Friday

Cantor Fitzgerald analyst Kristen Kluska maintains ADMA Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>) with a Overweight and raises the price target from $15 to $20.

Cantor Fitzgerald Maintains Overweight on ADMA Biologics, Raises Price Target to $20

Invesco Main Street Small Cap Fund Q2 2024 Review

Invesco Small Cap Equity Fund Q2 2024 Review

Invesco Small Cap Growth Fund Q2 2024 Review

Small-cap and mid-cap Health Care has room to rally - Roth MKM

CNH Industrial, Parsons and more join S&P MidCap 400

ADMA Biologics to join S&P SmallCap 600 index

American Century Small Cap Growth Fund Q2 2024 Commentary

ADMA Biologics: Riding High On ASCENIV's Success

The latest update is out from ADMA Biologics ( ($ADMA) ). ADMA Biologics, Inc. has reassured analysts that the recent change in auditors, detailed ...

Comments

ADMA Biologics

Noticias

Últimas noticias sobre ADMA Biologics (NASDAQ:ADMA) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL